mRCC

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

mRCC
Sep 14, 2024, 13:44 | Societies
Neeraj Agarwal's highlights from ESMO24
The ESMO Congress 2024 (ESMO24) is one of the most globally influential platforms in oncology,…
Sep 2, 2024, 08:35 | Insight
Shilpa Gupta: Novel approach of intermittent IO in mRCC
Shilpa Gupta shared a post on X by María Natalia Gandur Quiroga about a recent…
Aug 22, 2024, 15:12 | Blog
Intensification and de-intensification in the treatment of mRCC by Monty Pal - IUCS
International Urology Cancer Summit (IUCS) shared a post on LinkedIn: "New agents with novel MOAs…
Aug 18, 2024, 15:13 | Blog
Modupe Elebute-Odunsi: Community Engagement to Increase Cancer Prevention Awareness
Modupe Elebute-Odunsi, CEO/Founder at Marcelle Ruth Cancer Centre and Specialist Hospital, shared on LinkedIn: "COMMUNITY ENGAGEMENT…
Aug 5, 2024, 01:42 | Blog
Michael Harrison: Awesome to present on favorable risk mRCC at WorldGU24
Michael Harrison, GU medical oncologist at Duke Cancer Institute, shared a post on X: Awesome…
Jul 25, 2024, 13:04 | Blog
Enrique Grande: Failure of Trials to Enhance Outcomes in mRCC Patients Re-challenged with Immunotherapy
Enrique Grande shared a post on X: "2 phase 3 trials have failed to improve…
Jul 15, 2024, 11:50 | Blog
Karl Semaan: Renee Maria Saliby presented her results on intermediate endpoints in patients with mRCC at KCRS24
Karl Semaan, Postdoctoral Research Fellow at Dana-Farber Cancer Institute, shared a post on X: "Star…
Jul 12, 2024, 13:32 | Societies
Insights from KCRS24 by Neeraj Agarwal
Kidney Cancer Research Summit or the KCRS24 was a conference held on 11th-12th July in…
Jul 9, 2024, 07:25 | Insight
Piotr Wysocki: Checkpoint inhibitor and TKI combinations in GU malignancies
Piotr Wysocki recently posted on LinkedIn: "A phase I study (Apolo AB et al. J Clin…
Jul 1, 2024, 17:38 | Blog
Sara Elena Rebuzzi: Study protocol of the ongoing study on the first-line therapy in mRCC patients
Sara Elena Rebuzzi, Medical Oncologis at The Hospital of San Paolo, made the following post…
Jun 1, 2024, 11:55 | Societies
Cristiane Bergerot: Exciting findings from ASCO24 by Nazli Dizman et al.
Cristiane Bergerot shared a post on X: "Exciting findings from ASCO24: CBM588, a Clostridium butyricum-based…
May 25, 2024, 14:20 | Blog
Marc Machaalani: Immunotherapy rechallenge after prior immune checkpoint inhibition in mRCC
Marc Machaalani, Postdoctoral Research Fellow at Dana-Farber Cancer Institute, shared a post by ASCO on…
May 23, 2024, 06:36 | Insight
María Natalia Gandur Quiroga: New insights on immunotherapy rechallenge in mRCC
María Natalia Gandur Quiroga shared on X: "New insights on immunotherapy rechallenge in mRCC! Key…
May 21, 2024, 07:30 | Insight
Nazli Dizman: ICI rechallenge and future directions in mRCC
Nazli Dizman, a Hematology/Oncology Fellow at MD Anderson Cancer Center, shared a post by The…
Apr 28, 2024, 12:38 | Insight
Piotr Wysocki: Combined treatment (TKI+ICI) does not benefit favorable-risk mRCC patients
Piotr Wysocki recently shared on LinkedIn: "For several years, combined therapy based on the administration of…
Apr 23, 2024, 23:49 | Drugs
Yüksel Ürün: Updated 1st-line treatment in mRCC!
Yüksel Ürün, Doctorate Professor at the Faculty of Medicine, Ankara University, Turkey, shared a post…
All: 16 Posts: 1 - 100
Special Coverage